Raymond James & Associates Ardelyx, Inc. Transaction History
Raymond James & Associates
- $150 Billion
- Q2 2024
A detailed history of Raymond James & Associates transactions in Ardelyx, Inc. stock. As of the latest transaction made, Raymond James & Associates holds 20,211 shares of ARDX stock, worth $111,362. This represents 0.0% of its overall portfolio holdings.
Number of Shares
20,211
Previous 20,069
0.71%
Holding current value
$111,362
Previous $146,000
2.05%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding ARDX
# of Institutions
200Shares Held
141MCall Options Held
1.25MPut Options Held
1.52M-
Janus Henderson Group PLC London, X022MShares$121 Million0.09% of portfolio
-
Black Rock Inc. New York, NY17.1MShares$94.2 Million0.0% of portfolio
-
State Street Corp Boston, MA14.1MShares$77.6 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA13.4MShares$73.8 Million0.0% of portfolio
-
Eventide Asset Management, LLC Boston, MA6.81MShares$37.5 Million0.8% of portfolio
About ARDELYX, INC.
- Ticker ARDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 154,636,000
- Market Cap $852M
- Description
- Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel synd...